Beam Therapeutics Inc’s recently made public that its Chief Legal Officer Bellon Christine unloaded Company’s shares for reported $0.1 million on Apr 01 ’25. In the deal valued at $18.35 per share,5,674 shares were sold. As a result of this transaction, Bellon Christine now holds 117,294 shares worth roughly $2.13 million.
Then, Evans John M. sold 30,663 shares, generating $562,684 in total proceeds. Upon selling the shares at $18.35, the CEO now owns 986,249 shares.
Before that, Ciaramella Giuseppe sold 7,434 shares. Beam Therapeutics Inc shares valued at $136,418 were divested by the President at a price of $18.35 per share. As a result of the transaction, Ciaramella Giuseppe now holds 190,216 shares, worth roughly $3.46 million.
BofA Securities upgraded its Beam Therapeutics Inc [BEAM] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who increased its forecast for the stock in early March from “a Sector perform” to “a Sector outperform”. Cantor Fitzgerald also remained covering BEAM and has increased its forecast on January 29, 2025 with a “an Overweight” recommendation from previously “Neutral” rating. Leerink Partners revised its rating on November 06, 2024. It rated BEAM as “an Outperform” which previously was an “a Market perform”.
Price Performance Review of BEAM
On Monday, Beam Therapeutics Inc [NASDAQ:BEAM] saw its stock fall -2.18% to $18.17. Over the last five days, the stock has gained 12.23%. Beam Therapeutics Inc shares have fallen nearly -26.73% since the year began. Nevertheless, the stocks have fallen -25.81% over the past one year.
Levels Of Support And Resistance For BEAM Stock
The most recent change occurred on October 16, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating .
